Skip to content

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$179.44M-15.6%-$155.2M-4.2%-$148.97M+28.0%-$206.81M+1.0%-$208.93M-0.4%
$41.56M+10.5%$37.61M+1.6%$37.02M-8.7%$40.55M+1.7%$39.88M-11.1%
-$185.63M-9.7%-$169.25M-4.6%-$161.87M-5.0%-$154.18M+9.2%-$169.86M-7.9%
-$86.83M+39.5%-$143.48M-115%-$66.61M
$321.16M+3.9%$309.03M+39.3%$221.81M-7.3%$239.24M+0.2%$238.87M-41.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?
Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.